Oral antiviral treatments for COVID-19 : opportunities and challenges
© 2022. The Author(s)..
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication and prevent disease progression to a more severe form. However, the timing of antiviral treatment plays a crucial role in this regard. Oral antiviral drugs provide an opportunity to manage SARS-CoV-2 infection without a need for hospital admission, easing the general burden that COVID-19 can have on the healthcare system. This review paper (i) presents the potential pharmaceutical antiviral targets, including various host-based targets and viral-based targets, (ii) characterizes the first-generation anti-SARS-CoV-2 oral drugs (nirmatrelvir/ritonavir and molnupiravir), (iii) summarizes the clinical progress of other oral antivirals for use in COVID-19, (iv) discusses ethical issues in such clinical trials and (v) presents challenges associated with the use of oral antivirals in clinical practice. Oral COVID-19 antivirals represent a part of the strategy to adapt to long-term co-existence with SARS-CoV-2 in a manner that prevents healthcare from being overwhelmed. It is pivotal to ensure equal and fair global access to the currently available oral antivirals and those authorized in the future.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Pharmacological reports : PR - 74(2022), 6 vom: 01. Dez., Seite 1255-1278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rahmah, Laila [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 15.12.2022 published: Print-Electronic ErratumIn: Pharmacol Rep. 2022 Sep 23;:. - PMID 36149599 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43440-022-00388-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343916142 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343916142 | ||
| 003 | DE-627 | ||
| 005 | 20231226021546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-022-00388-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343916142 | ||
| 035 | |a (NLM)35871712 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rahmah, Laila |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral antiviral treatments for COVID-19 |b opportunities and challenges |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Pharmacol Rep. 2022 Sep 23;:. - PMID 36149599 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication and prevent disease progression to a more severe form. However, the timing of antiviral treatment plays a crucial role in this regard. Oral antiviral drugs provide an opportunity to manage SARS-CoV-2 infection without a need for hospital admission, easing the general burden that COVID-19 can have on the healthcare system. This review paper (i) presents the potential pharmaceutical antiviral targets, including various host-based targets and viral-based targets, (ii) characterizes the first-generation anti-SARS-CoV-2 oral drugs (nirmatrelvir/ritonavir and molnupiravir), (iii) summarizes the clinical progress of other oral antivirals for use in COVID-19, (iv) discusses ethical issues in such clinical trials and (v) presents challenges associated with the use of oral antivirals in clinical practice. Oral COVID-19 antivirals represent a part of the strategy to adapt to long-term co-existence with SARS-CoV-2 in a manner that prevents healthcare from being overwhelmed. It is pivotal to ensure equal and fair global access to the currently available oral antivirals and those authorized in the future | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antivirals | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Pandemic | |
| 650 | 4 | |a Pharmaceutical treatment | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Abarikwu, Sunny O |e verfasserin |4 aut | |
| 700 | 1 | |a Arero, Amanuel Godana |e verfasserin |4 aut | |
| 700 | 1 | |a Essouma, Mickael |e verfasserin |4 aut | |
| 700 | 1 | |a Jibril, Aliyu Tijani |e verfasserin |4 aut | |
| 700 | 1 | |a Fal, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Flisiak, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Makuku, Rangarirai |e verfasserin |4 aut | |
| 700 | 1 | |a Marquez, Leander |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Kawthar |e verfasserin |4 aut | |
| 700 | 1 | |a Ndow, Lamin |e verfasserin |4 aut | |
| 700 | 1 | |a Zarębska-Michaluk, Dorota |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
| 700 | 1 | |a Rzymski, Piotr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports : PR |d 2005 |g 74(2022), 6 vom: 01. Dez., Seite 1255-1278 |w (DE-627)NLM154978965 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:6 |g day:01 |g month:12 |g pages:1255-1278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43440-022-00388-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 6 |b 01 |c 12 |h 1255-1278 | ||